Luciferase in vivo expression technology: use of recombinant mycobacterial reporter strains to evaluate antimycobacterial activity in mice.
The development of new drugs and vaccines directed against Mycobacterium tuberculosis is severely impeded by the slow growth of this organism and the need to work under stringent biosafety conditions. These difficulties pose considerable obstacles when animal studies with M. tuberculosis are performed. We investigated whether a novel approach termed luciferase in vivo expression, using an enhanced luciferase-expressing mycobacterial strain, could be used to evaluate antimycobacterial activity in mice. Vectors that expressed firefly luciferase (lux gene) at high levels in the bacillus Calmette-Gu-erin (BCG) strain of Mycobacterium bovis were constructed for use in vivo. One recombinant BCG reporter strain (rBCG-lux) was selected for high-level expression of the lux gene product and for its ability to replicate in mice. Methodology to monitor in vivo growth of the rBCG-lux reporter strain in mice by direct assay of luciferase luminescence in organ homogenates was developed. The utility of this approach for assessing the in vivo efficacies of antimycobacterial compounds was evaluated. The activities of standard antimycobacterial drugs were directly apparent in mice infected with the rBCG-lux reporter strain by statistically significant reductions in spleen luminescence. In addition, antimycobacterial immunity was also evident in BCG-immunized mice, in which suppression of rBCG-lux growth in comparison with that in naive mice was clearly observed. The use of luciferase in vivo expression for the in vivo evaluation of antimycobacterial activity compared favorably with standard CFU determinations in terms of time, labor, expense, and statistical significance but permitted the evaluation of antimycobacterial drugs and immunity in mice in 7 days or less. Thus, the use of this technology can greatly accelerate the process of evaluation of antibiotics and immunogens in animal models for the slowly growing pathogenic mycobacteria.
Hickey
M J
MJ
Department of Molecular Microbiology, PathoGenesis Corporation, Seattle, Washington 98119, USA.
Arain
T M
TM
Shawar
R M
RM
Humble
D J
DJ
Langhorne
M H
MH
Morgenroth
J N
JN
Stover
C K
CK
D000818:Animals; D000995:Antitubercular Agents / Q000627:therapeutic use*; D015169:Colony Count, Microbial; D003520:Cyclophosphamide / Q000494:pharmacology; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D018274:Electroporation; D005260:Female; D007166:Immunosuppressive Agents / Q000494:pharmacology; D008156:Luciferases / Q000096:biosynthesis* / Q000235:genetics; D008163:Luminescent Measurements; D051379:Mice; D008807:Mice, Inbred BALB C; D009163:Mycobacterium bovis / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism; D011994:Recombinant Proteins / Q000096:biosynthesis; D013154:Spleen / Q000187:drug effects / Q000382:microbiology; D014162:Transfection; D014376:Tuberculosis / Q000188:drug therapy*
D000995:Antitubercular Agents; D007166:Immunosuppressive Agents; D011994:Recombinant Proteins; D003520:Cyclophosphamide; D008156:Luciferases